News

Catch up on coverage from the first day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Raj Chovatiya, MD, PhD, MSCI, discusses how early-career dermatologists can gain the most benefit from this year’s annual meeting.

Jeanine Downie, MD, FAAD, discussed critical updates on tattoo ink safety, new dermatologic technologies, biostimulators, and more at AAD 2025.

The phase 2 trial of bimiralisib gel shows promising efficacy and safety for actinic keratosis, with up to 70% lesion clearance.

In addition to Taylor, several other new leaders have been appointed to key roles within the AAD to help drive its mission of advancing dermatology.

Along with his session insights on diet and chronic spontaneous urticaria, Friedman shares tips for navigating the largest dermatology conference in the US.

Ahead of the annual meeting, Dermatology Times spoke with Draelos about why she looks forward to the meeting each year.

Adamson highlights key topics to expect at the AAD Annual Meeting, emphasizing the importance of tackling controversial issues and fostering collaboration.

The company showcased advancements in tirbanibulin and its early-stage antibody LAD191.

Published in JID, the study analyzes data from the FDA’s FAERS database to examine cases of neoplasms—including skin and breast cancers—potentially associated with benzoyl peroxide use.

Read more on how to navigate all the opportunities at this year’s AAD meeting, which starts today in Orlando, Florida.

The analyzed dataset included over 200,000 patients with vitiligo to find trends in diagnosis, treatment, and more.

The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval.

Serota and other field experts discussed best practices as well as new therapeutics.

Among the many sessions to be held at the American Academy of Dermatology Annual Meeting in Orlando, Florida, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

Patrick Burnett, MD, PhD, shares key updates expected in 2025 for therapeutics treating atopic dermatitis, alopecia areata, and more.

Experts discussed laser and light-based therapies for acne, rosacea, hyperpigmentation, and inflammatory skin diseases.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At AAAAI/WAO 2025, Bernstein explored new findings on rilzabrutinib and dupilumab in CSU, highlighting treatment gaps and future therapies.

The novel formulation improved the appearance of dry and chapped lips after 28 days of use.

Experts discussed personalized approaches to atopic dermatitis, from steroid-sparing topicals to biologics, highlighting rapid relief and long-term management strategies.

Robinson shared insights into how the company is working to fight clinical research disparities.

The novel formulations will harness Quoin’s Invisicare technology to treat microcystic lymphatic malformations, venous malformations, and angiofibromas.

Psoriasis trials are among the least diverse within dermatology, with participants predominantly being white men.

Dematology Times' Editor in Chief interviews Adelaide Hebert, MD, who will be honored at the AAD 2025 Legacy Celebration for her impact on pediatric dermatology.

A new survey reveals widespread misunderstanding and lack of effective treatments in chronic hand eczema.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

In a conversation with Kristy Hamilton, MD, FACS, she spoke about the recent aesthetic trend and how clinicians can align with new patient expectations.

Research suggests that rebalancing the skin microbiome with pre-, post-, and probiotics may improve AD symptoms.

Experts discussed pediatric atopic dermatitis, treatment innovations, disease burden, and the latest topical and systemic therapies in a DermView video series.